Lee S Simon
Affiliation: Harvard University
- A Food and Drug Administration primerLee S Simon
Harvard Medical School, Beth Israel Deaconess Medical Center, 110 Francis Street 4B, Boston, MA 02115, USA
Arthritis Rheum 55:4-8. 2006
- OsteoporosisLee S Simon
Harvard Medical School, Beth Israel Deaconess Hospital, 330 Brookline Avenue, Boston, MA 02215, USA
Rheum Dis Clin North Am 33:149-76. 2007..Effective therapies are available for the patient who has arthritic osteoporosis. The approach is critical to ensure an optimal quality of life in these individuals who suffer with a disease that is clearly treatable...
- Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of riskLawrence Goldkind
Department of Gastroenterology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
Arthritis Res Ther 8:105. 2006....
- Is milnacipran effective in treating pain in patients with fibromyalgia?Lee S Simon
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Nat Clin Pract Rheumatol 2:126-7. 2006
- The COX 2 selective inhibitors: what the newspapers have not told youLee S Simon
Harvard Medical School, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Bull NYU Hosp Jt Dis 65:229-41. 2007
- Preliminary development of a responder index for chronic low back painLee S Simon
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02465, USA
J Rheumatol 34:1386-91. 2007..The aim of the OMERACT Special Interest Group was to discuss the development and validation of a preliminary responder index in CLBP...
- The COX-2 inhibitors: a reasoned review of the dataLee S Simon
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Swiss Med Wkly 135:419-24. 2005....
- A world without Vioxx: to COX-2 or not to COX-2?Lee S Simon
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
Cleve Clin J Med 71:849-50, 852, 854 passim. 2004
- The treatment of rheumatoid arthritisLee S Simon
Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis St Suite 4B, Boston, MA 02215, USA
Best Pract Res Clin Rheumatol 18:507-38. 2004....
- How to ascertain drug safety in the context of benefit. Controversies and concernsLee S Simon
Harvard Medical School, Boston, MA, USA
J Rheumatol 36:2114-21. 2009..Each attendee spoke on a given topic and the group was charged to consider the issue of risk in the context of formally posed questions. This article provides a summary of the presentations and outlines the discussions that followed...
- OsteoporosisLee S Simon
Harvard Medical School, Beth Isreal Deaconess Hospital, 330 Brookline Avenue, Boston, MA 02215, USA
Clin Geriatr Med 21:603-29, viii. 2005..Newer therapies such as parathyroid hormone may improve the fracture risk even more than biphosphonates over a shorter period of time...
- Analysis of aspirin-associated risks in healthy individualsChin Hur
Harvard Medical School, Institute for Technology Assessment and Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114 4719, USA
Ann Pharmacother 39:51-7. 2005..Aspirin therapy is widely accepted for patients with documented cardiovascular disease, but there is a growing trend among healthy individuals to use aspirin as primary prevention for both cardiovascular disease and cancer...
- The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individualsChin Hur
Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, 10th Floor, Boston, MA 02114, USA
Cancer 101:189-97. 2004..Accruing evidence suggests that cyclooxygenase-2-selective inhibitors (coxibs) may be effective for colorectal carcinoma (CRC) chemoprevention but would not provide the primary cardiac benefit of aspirin...
- Controversies in COX-2 selective inhibitionLee S Simon
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Rheumatol 29:1501-10. 2002
- Perception of risk: the state of COX-2 selective inhibitorsLee S Simon
Harvard Medical School, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 5A, Boston, MA 02115, USA
Curr Rheumatol Rep 7:163-6. 2005
- Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritisLee S Simon
SDG LLC Consulting, 124 Mt Auburn Street, Cambridge, MA, USA
Pain 143:238-45. 2009..TDiclo in DMSO vehicle is an effective treatment option for knee osteoarthritis with efficacy similar to, but tolerability better than ODiclo. DMSO vehicle was no more efficacious than placebo...
- Observations from the OMERACT Drug Safety Summit, May 2008Lee S Simon
Harvard Medical School, Boston, MA, USA
J Rheumatol 36:2110-3. 2009..At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions...
- American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trialsDavid T Felson
Boston University School of Medicine, Boston, Massachusetts, USA
Arthritis Rheum 63:573-86. 2011..This work was undertaken to develop such a definition...
- Patient-reported outcomes in chronic gout: a report from OMERACT 10Jasvinder A Singh
Medicine Service, Birmingham Veterans Affairs VA Medical Center and Division of Rheumatology, Department of Medicine, University of Alabama, Birmingham, AL 35294, USA
J Rheumatol 38:1452-7. 2011..To summarize the endorsement of measures of patient-reported outcome (PRO) domains in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10)...
- Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study GroupLeslie J Crofford
Center for the Advancement of Women s Health, University of Kentucky, Lexington, Kentucky, USA
J Rheumatol 33:1403-8. 2006....
- Chronic pain and fibromyalgia: the regulatory perspectiveJames Witter
Division of Anti inflammatory, Analgesic and Ophthalmic Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA
Best Pract Res Clin Rheumatol 17:541-6. 2003..It will also begin to familiarize the reader with the importance of the so-called 'label' and some of its roles to enable the best 'risk-benefit' decisions be made for, and by, patients with chronic pain...
- The use of rheumatoid arthritis health-related quality of life patient questionnaires in clinical practice: lessons learnedSimcha M Russak
Zynx Health Incorporated, Beverly Hills, California, USA
Arthritis Rheum 49:574-84. 2003....
- The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitusJames R Sowers
State University of New York, Brooklyn, USA
Arch Intern Med 165:161-8. 2005..Therefore, we conducted a double-blind, randomized trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-hour blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis...
- Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balanceJeffrey S Borer
The Howard Gilman Institute for Valvular Heart Diseases at Weill Medical College of Cornell University, New York, New York, USA
Arthritis Res Ther 7:S14-22. 2005....
- Minimal disease activity for rheumatoid arthritis: a preliminary definitionGeorge A Wells
Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
J Rheumatol 32:2016-24. 2005..This set of 2 definitions gained approval of 73% of the attendees. These (and other) definitions will now be subject to further validation in other databases...
- Fibromyalgia syndromePhilip J Mease
Swedish Medical Center, The University of Washington School of Medicine, Seattle, WA, USA
J Rheumatol 32:2270-7. 2005..A prioritized list of domains of FM to be investigated was thus developed, key issues and controversies in the field were debated, and consensus on a research agenda on outcome measure development was reached...
- Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis stClifton O Bingham
Division of Rheumatology, Johns Hopkins University, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Room 404, Baltimore, MD 21224, USA
Arthritis Rheum 54:3494-507. 2006....
- Hyperbole, innuendo, and fact: the strange case of COX-2 selective inhibitorsLee S Simon
J Rheumatol 33:1-3. 2006